SCHEMBL9049241

SCHEMBL9049241

Oc1ccnc(F)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29695972 1.00
Methane SCHEMBL29058857 0.97
SCHEMBL28480049 0.75 ESR2 (0.48)
SCHEMBL29518274 0.72
SCHEMBL22068158 0.72 IDO1 (0.55)
SCHEMBL29351542 0.72
SCHEMBL243030 0.72
SCHEMBL1697620 0.72
SCHEMBL1071219 0.72 CCR1 (0.48)
SCHEMBL12185880 0.71 NQO2 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013755-B1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS NOVARTIS AG (CH) 2025-01-08 EP claimed
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NOVARTIS AG (CH) 2022-08-23 US claimed
US-12630510-B2 EP2 antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2026-05-19 US disclosed
US-12564636-B2 Pnictogen-containing heterocyclic compounds and their use UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) 2026-03-03 US disclosed
US-20250388604-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2025-12-25 US disclosed
EP-3992176-B1 EP2 ANTAGONIST ONO PHARMACEUTICAL CO (JP) 2025-08-27 EP disclosed
EP-4572762-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 EP disclosed
US-20240352023-A1 IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-10-24 US disclosed
US-20240285772-A1 PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE COLGATE UNIVERSITY 2024-08-29 US disclosed
US-12037338-B2 Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-07-16 US disclosed
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS VERNALIS (R&D) LTD (GB) 2024-05-09 US disclosed
EP-2894148-A1 NOVEL SMECTIC PHASE A LIQUID CRYSTAL MATERIAL Halation Photonics Corporation (CN) 2015-07-15 EP disclosed
US-9051325-B2 Bicyclic [5,6] imidazo pyrimodone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2015-06-09 US disclosed
WO-2014137883-A1 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2014-09-12 WO disclosed
WO-2014137883-A1 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2014-09-12 WO disclosed
US-20140213599-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-07-31 US disclosed
WO-2014114694-A1 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-07-31 WO disclosed
US-20140160384-A1 SMECTIC A-PHASE LIQUID CRYSTAL MATERIAL HALATION PHOTONICS CORPORATION (CN) 2014-06-12 US disclosed
WO-2013105753-A1 SUBSTITUTED PIPERIDINE DERIVATIVES AND METHODS FOR PREPARING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2013-07-18 WO disclosed
EP-0540673-B1 ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LAB (US) 1996-10-16 EP disclosed